ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1995

Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset?

Sofia Pedro1, Ted R. Mikuls2 and Kaleb Michaud3, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: infection and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Session Title: ACR Plenary Session II: Discovery 2015

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Elderly-onset RA (EORA) patients (age of
onset>60) are less likely to be treated with biologics even when accounting
for disease activity compared to young-onset RA (YORA) patients (age<60) at
the same age. We hypothesize that this difference is related to an increased
risk of serious infections in EORA vs. YORA patients.

Methods: Participants with RA were followed biannually
from 1998 through 2014 in a large US longitudinal study. Each EORA patient was
matched to 3 YORA patients based on age, sex, and calendar year of study entry,
which required all patients to have age>60. Serious infections were defined
as those requiring hospitalization, intravenous antibiotics, or led to death
within a year after the patient’s last observation. Infections were validated
from hospitalization, physician, and death records. Survival analysis methods
(Cox regression, time to first infection using time-varying covariates and
Andersen-Gill multiple failures model) were applied. Confounders included ethnicity,
comorbidity index, HAQ, pain, education, prednisone use, urban vs. rural home,
previous serious infection, and prior number of DMARDs. DMARD treatments were
grouped using the following hierarchical classification: monotherapy
MTX (reference), none, non-cytotoxic DMARD, cytotoxic DMARD, TNF, and non-TNF
biologic. A risk window of 3 months was considered for all DMARDs except
rituximab within the non-TNF group had 12 months.

Results: A total of 1,865 EORA patients were matched
with 5,595 YORA patients. In both groups, 25% were male and 91% white and a median
age between 65-70. EORA and YORA patients had 4.4 (4.2) and 20.9 (12.6) years
of RA duration, respectively. Self-reported prior infections were 4.1% and 7.1%
for EORA and YORA patients, respectively (P<0.01). There were 1,198 serious
infections, 207 (11.0%) in EORA and 998 (17.8%) in YORA patients. Figure
presents incident rates (first and multiple) by age group. Adjusted for other
confounders, the HR of EORA vs. YORA was 0.84 (0.64-1.11) for first infection
and 1.03 (0.86-1.23) for multiple. Prednisone, cytotoxic DMARDs, and no DMARD
treatment were associated with an increased risk of serious infections as well
as worse HAQ or pain, prior infections, and comorbidities (Table). Sensitivity
analysis stratified patients by decade of age and no differences were found.

Conclusion: We found no increased risk of serious
infections in EORA vs. YORA patients. Our results support providing similar
treatment for EORA patients as done for elderly YORA patients

Figure. Serious infection incidence rates by decade of
age.


Table. Cox regression for time to first infection and
multiple infections.

Time to first infection

Time to multiple infections

Haz. Ratio

95% CI

Haz. Ratio

95% CI

EORA (vs. YORA)

0.84

(0.64 -1.11)

1.03

(0.86 -1.23)

DMARD treatment (Hierar.)

ref. monotherapy MTX

  None 

1.24

(0.98 -1.56)

1.24

(1.06 -1.47)

  Non-cytotoxic DMARD*¤

0.72

(0.56 -0.93)

0.82

(0.69 -0.98)

  Cytotoxic DMARD

1.04

(0.78 -1.39)

1.14

(0.93 -1.40)

  TNF biologic

0.91

(0.72 -1.15)

0.96

(0.81 -1.13)

  Non-TNF biologic*¤

0.43

(0.25 -0.75)

0.48

(0.33 -0.69)

Prednisone*¤

2.19

(1.88 -2.54)

2.08

(1.87 -2.31)

Male*¤

1.37

(1.16 -1.62)

1.42

(1.26 -1.60)

Age*¤

1.36

(1.09 -1.69)

1.23

(1.07 -1.40)

Age-squared*¤

1.00

(1.00 -1.00)

1.00

(1.00 -1.00)

RA Duration (log yrs)

0.97

(0.84 -1.11)

1.07

(0.97 -1.19)

Caucasion*¤

1.77

(1.25 -2.50)

1.80

(1.38 -2.34)

HAQ (0-3)*¤

1.43

(1.27 -1.61)

1.47

(1.35 -1.59)

Pain (0-10)*¤

1.05

(1.02 -1.08)

1.04

(1.01 -1.06)

Education (yrs)¤

0.98

(0.95 -1.01)

0.97

(0.95 -0.99)

Cormorbidity index (0-9)*¤

1.18

(1.13 -1.24)

1.19

(1.15 -1.23)

# of prior DMARDs (log)*¤

1.14

(1.03 -1.25)

1.10

(1.04 -1.18)

# of prior biologics (log)

1.04

(0.92 -1.19)

1.05

(0.97 -1.15)

Urban (vs. rural)*¤

1.17

(1.00 -1.36)

1.13

(1.01 -1.26)

Prior infection¤

1.23

(0.96 -1.57)

1.49

(1.27 -1.75)

*P<0.01 for time to first infection; ¤P<0.01 for time to multiple infections


Disclosure: S. Pedro, None; T. R. Mikuls, None; K. Michaud, None.

To cite this abstract in AMA style:

Pedro S, Mikuls TR, Michaud K. Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/does-the-risk-of-serious-infections-among-elderly-ra-patients-differ-by-age-of-disease-onset/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-the-risk-of-serious-infections-among-elderly-ra-patients-differ-by-age-of-disease-onset/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences